Edgewise Therapeutics, Inc.
EWTX
Rang in Aktien
#3885
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aktienkurs
$39.60
Marktkapitalisierung
$4.26B
Veränderung (1 Tag)
-0.38%
Veränderung (1 Jahr)
155.32%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategorie
Healthcare
Kursverlauf für Edgewise Therapeutics, Inc. (EWTX)
Höchster Schlusskurs: $38.97 am 2026-10-01
Niedrigster Schlusskurs: $32.43 am 2021-03-01
Niedrigster Schlusskurs: $32.43 am 2021-03-01
Kursverlauf der Aktie von Edgewise Therapeutics, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 37.71% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
